Allogene Therapeutics, Inc. (NASDAQ:ALLO) Shares Purchased by Susquehanna Fundamental Investments LLC

Susquehanna Fundamental Investments LLC boosted its stake in shares of Allogene Therapeutics, Inc. (NASDAQ:ALLO) by 46.2% in the second quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The firm owned 418,699 shares of the company’s stock after acquiring an additional 132,291 shares during the quarter. Susquehanna Fundamental Investments LLC owned about 0.20% of Allogene Therapeutics worth $976,000 as of its most recent filing with the Securities and Exchange Commission.

Several other hedge funds and other institutional investors also recently modified their holdings of ALLO. Bourgeon Capital Management LLC lifted its holdings in shares of Allogene Therapeutics by 12.8% during the first quarter. Bourgeon Capital Management LLC now owns 57,200 shares of the company’s stock worth $256,000 after purchasing an additional 6,500 shares during the period. CANADA LIFE ASSURANCE Co raised its position in Allogene Therapeutics by 85.1% during the 1st quarter. CANADA LIFE ASSURANCE Co now owns 17,750 shares of the company’s stock worth $79,000 after buying an additional 8,162 shares during the last quarter. Nisa Investment Advisors LLC lifted its stake in shares of Allogene Therapeutics by 429.6% in the 2nd quarter. Nisa Investment Advisors LLC now owns 10,767 shares of the company’s stock worth $25,000 after acquiring an additional 8,734 shares during the period. Arizona State Retirement System boosted its holdings in shares of Allogene Therapeutics by 36.1% in the second quarter. Arizona State Retirement System now owns 40,915 shares of the company’s stock valued at $95,000 after acquiring an additional 10,855 shares in the last quarter. Finally, Federated Hermes Inc. acquired a new position in shares of Allogene Therapeutics during the second quarter worth about $29,000. 83.63% of the stock is currently owned by hedge funds and other institutional investors.

Allogene Therapeutics Stock Down 5.2 %

Allogene Therapeutics stock opened at $2.53 on Thursday. The firm’s 50-day simple moving average is $2.66 and its 200 day simple moving average is $2.90. Allogene Therapeutics, Inc. has a 52 week low of $2.01 and a 52 week high of $5.78. The firm has a market capitalization of $528.77 million, a PE ratio of -1.41 and a beta of 0.83.

Allogene Therapeutics (NASDAQ:ALLO) last released its quarterly earnings results on Wednesday, August 7th. The company reported ($0.32) EPS for the quarter, beating the consensus estimate of ($0.35) by $0.03. Allogene Therapeutics had a negative net margin of 223,139.98% and a negative return on equity of 50.24%. On average, research analysts expect that Allogene Therapeutics, Inc. will post -1.38 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

A number of equities research analysts recently commented on the stock. Truist Financial restated a “buy” rating and issued a $14.00 price objective (down previously from $17.00) on shares of Allogene Therapeutics in a research report on Friday, August 9th. HC Wainwright restated a “buy” rating and issued a $9.00 price target on shares of Allogene Therapeutics in a research note on Thursday, August 15th. Canaccord Genuity Group dropped their price objective on Allogene Therapeutics from $35.00 to $14.00 and set a “buy” rating on the stock in a report on Thursday, August 8th. Oppenheimer assumed coverage on shares of Allogene Therapeutics in a research report on Thursday, August 8th. They set an “outperform” rating and a $11.00 target price on the stock. Finally, Citigroup upped their price target on shares of Allogene Therapeutics from $7.00 to $8.00 and gave the stock a “buy” rating in a research note on Friday, August 9th. Three investment analysts have rated the stock with a hold rating and eight have issued a buy rating to the company. Based on data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and an average target price of $9.96.

Allogene Therapeutics Profile

Allogene Therapeutics, Inc, a clinical stage immuno-oncology company, develops and commercializes genetically engineered allogeneic T cell therapies for the treatment of cancer. It develops, manufactures, and commercializes UCART19, an allogeneic chimeric antigen receptor (CAR) T cell product candidate for the treatment of pediatric and adult patients with R/R CD19 positive B-cell acute lymphoblastic leukemia (ALL).